It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
Subscribe To Our Newsletter & Stay Updated
